Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model

Bergogne-Berezin, 1996, Acinetobacter spp. As nosocomial pathogens: microbiological, clinical, and epidemiological features, Clin Microbiol Rev, 9, 148, 10.1128/CMR.9.2.148 Dijkshoorn, 2007, An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii, Nat Rev Microbiol, 5, 939, 10.1038/nrmicro1789 Denys, 2013, Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the tigecycline evaluation and surveillance trial (T.E.S.T.), Ann Clin Microbiol Antimicrob, 12, 24, 10.1186/1476-0711-12-24 Bou, 2000, Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC β-lactamase in Acinetobacter baumannii, Antimicrob Agents Chemother, 44, 428, 10.1128/AAC.44.2.428-432.2000 Damier-Piolle, 2008, AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii, Antimicrob Agents Chemother, 52, 557, 10.1128/AAC.00732-07 Gootz, 2008, Acinetobacter baumannii: an emerging multidrug-resistant threat, Expert Rev Anti Infect Ther, 6, 309, 10.1586/14787210.6.3.309 Gordon, 2010, Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance, Int J Antimicrob Agents, 35, 219, 10.1016/j.ijantimicag.2009.10.024 Zavascki, 2010, Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy, Expert Rev Anti Infect Ther, 8, 71, 10.1586/eri.09.108 Karthikeyan, 2010, Coexistence of blaoxa-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from india, J Antimicrob Chemother, 65, 2253, 10.1093/jac/dkq273 Kumarasamy, 2010, Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study, Lancet Infect Dis, 10, 597, 10.1016/S1473-3099(10)70143-2 Park, 2010, Extensively drug-resistant Acinetobacter baumannii: risk factors for acquisition and prevalent OXA-type carbapenemases-a multicentre study, Int J Antimicrob Agents, 36, 430, 10.1016/j.ijantimicag.2010.06.049 Arroyo, 2011, The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A, Antimicrob Agents Chemother, 55, 3743, 10.1128/AAC.00256-11 Cai, 2012, Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies, J Antimicrob Chemother, 67, 1607, 10.1093/jac/dks084 Chen, 2012, Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the tigecycline in vitro surveillance in Taiwan study, 2006 to 2010, Antimicrob Agents Chemother, 56, 1452, 10.1128/AAC.06053-11 Park, 2011, Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii, Int J Antimicrob Agents, 37, 525, 10.1016/j.ijantimicag.2011.02.008 Craig, 1998, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin Infect Dis, 26, 1, 10.1086/516284 Andes, 2002, Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models, Antimicrob Agents Chemother, 46, 1665, 10.1128/AAC.46.6.1665-1670.2002 Andes, 2003, Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model, Antimicrob Agents Chemother, 47, 3935, 10.1128/AAC.47.12.3935-3941.2003 Sugihara, 2010, In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model, Antimicrob Agents Chemother, 54, 5298, 10.1128/AAC.00267-10 Chiba, 2012, DS-8587, a new generation of broad spectrum quinolone: antibacterial spectrum and its in vitro activities against clinical isolates in Japan Clinical and Laboratory Standards Institute, 2012 Kobayashi, 2012, DS-8587, a new generation of broad spectrum qinolone: non-clinical and clinical pharmacokinetic profiles Shields, 2012, Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients, PLoS One, 7, e52349, 10.1371/journal.pone.0052349 Schafer, 2007, Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii, Pharmacotherapy, 27, 980, 10.1592/phco.27.7.980 Higuchi, 2013, Potent in vitro antibacterial activity of DS-8587, a novel broad-spectrum quinolone, against Acinetobacter baumannii, Antimicrob Agents Chemother, 57, 1978, 10.1128/AAC.02374-12 Clark, 2008, In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci, Antimicrob Agents Chemother, 52, 77, 10.1128/AAC.01229-07 Wagenlehner, 2006, Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose, Int J Antimicrob Agents, 27, 7, 10.1016/j.ijantimicag.2005.09.014 Pandya, 2012, DS-8587, a new generation of broad spectrum quinolone: pharmacodynamics and in vivo efficacy against Acintobacter baumannii